UNSPSC 51401566: Lorazepam glucuronide

This classification denotes a benzodiazepine and antiemetic agent with the molecular formula C21H18Cl2N2O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P0G8I56129, chemically known as .beta.-d-glucopyranosiduronic acid, 7-chloro-5-(2-chlorophenyl)-2,3-dihydro-2-oxo-1h-1,4-benzodiazepin-3-yl, but more generally known as lorazepam glucuronide, which bears US NIH Compound Identifier 62966.

European Medicines Agency schedules lorazepam glucuronide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08582MIG. Most nations, for tariff purposes, schedule lorazepam glucuronide under HS 29339190. SMILES: C1CCC(C(C1)C2=NC(C(=O)NC3C2CC(CC3)CL)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O)CL.

UNSPSC 51401566 Lorazepam glucuronide, a Commodity code, does not align with the recent state and local procurement activity tagged under it. The single recent opportunity on record—Seminole County, Florida's IFB 60459723LAS, posted June 30, 2026, with a response deadline of July 26, 2023—solicits naloxone and drug deactivation systems for community health initiatives, not lorazepam glucuronide or pharmaceutical metabolites. The mismatch suggests either a classification error in the source data or that state and local procurement offices are applying the code inconsistently.

The code shows no relevant recent activity aligned with its nominal scope. No state or local opportunities targeting lorazepam glucuronide or related pharmaceutical compounds appear in the available records. Without evidence of actual procurement demand under this code, the opportunity pipeline cannot be characterized.